相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pharmacokinetic profile of the selective 5-HT3 receptor antagonist ondansetron in the rat: an original study and a minireview of the behavioural pharmacological literature in the rat
Cynthia Kwan et al.
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY (2020)
Ondansetron, a highly selective 5-HT3 receptor antagonist, reduces L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease
Cynthia Kwan et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2020)
Selective metabotropic glutamate receptor 2 positive allosteric modulation alleviates L-DOPA-induced psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset
Lamia Sid-Otmane et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2020)
The MPTP-lesioned marmoset model of Parkinson's disease: proposed efficacy thresholds that may potentially predict successful clinical trial results
Francis Beaudry et al.
JOURNAL OF NEURAL TRANSMISSION (2020)
Highly sensitive HPLC-MS/MS assay for the quantitation of ondansetron in rat plasma and rat brain tissue homogenate following administration of a very low subcutaneous dose
Fleur Gaudette et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2019)
Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review
Klaus Seppi et al.
MOVEMENT DISORDERS (2019)
5-HT2A blockade for dyskinesia and psychosis in Parkinson's disease: is there a limit to the efficacy of this approach? A study in the MPTP-lesioned marmoset and a literature mini-review
Cynthia Kwan et al.
EXPERIMENTAL BRAIN RESEARCH (2019)
Anti-dyskinetic efficacy of 5-HT3 receptor antagonist in the hemi-parkinsonian rat model
Nazanin Aboulghasemi et al.
IBRO REPORTS (2019)
Development of a selective and sensitive high-performance liquid chromatography-tandem mass spectrometry assay to support pharmacokinetic studies of LY-487,379 in rat and marmoset
Fleur Gaudette et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2018)
Predictive Value of Parkinsonian Primates in Pharmacologic Studies: A Comparison between the Macaque, Marmoset, and Squirrel Monkey
Nicolas Veyres et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2018)
Difficult choices in treating Parkinson's disease psychosis
[Anonymous]
LANCET NEUROLOGY (2018)
International Parkinson and Movement Disorder Society Evidence-Based Medicine Review: Update on Treatments for the Motor Symptoms of Parkinson's Disease
Susan H. Fox et al.
MOVEMENT DISORDERS (2018)
The highly selective 5-HT2A antagonist EMD-281,014 reduces dyskinesia and psychosis in the L-DOPA-treated parkinsonian marmoset
Adjia Hamadjida et al.
NEUROPHARMACOLOGY (2018)
Pharmacokinetic/Pharmacodynamic Correlation Analysis of Amantadine for Levodopa-Induced Dyskinesia
Elizabeth F. Brigham et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2018)
Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
E. Ray Dorsey et al.
LANCET NEUROLOGY (2018)
Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method to quantify LY-354,740 in rat and marmoset plasma
Fleur Gaudette et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2017)
Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015
Valery L. Feigin et al.
LANCET NEUROLOGY (2017)
The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmoset
Adjia Hamadjida et al.
PSYCHOPHARMACOLOGY (2017)
Psychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management
Anna Chang et al.
DRUGS (2016)
Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study)
Rajesh Pahwa et al.
MOVEMENT DISORDERS (2015)
Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial
Jeffrey Cummings et al.
LANCET (2014)
Combined Fenobam and Amantadine Treatment Promotes Robust Antidyskinetic Effects in the 1-Methyl-4-Phenyl1,2,3,6-Tetrahydropyridine ( MPTP)-Lesioned Primate Model of Parkinson's Disease
Wai Kin D. Ko et al.
MOVEMENT DISORDERS (2014)
Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia
Erwan Bezard et al.
MOVEMENT DISORDERS (2013)
Safinamide reduces dyskinesias and prolongs L-DOPA antiparkinsonian effect in parkinsonian monkeys
Laurent Gregoire et al.
PARKINSONISM & RELATED DISORDERS (2013)
Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease
Christopher Kobylecki et al.
MOVEMENT DISORDERS (2011)
Neuropsychiatric Behaviors in the MPTP Marmoset Model of Parkinson's Disease
Susan H. Fox et al.
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES (2010)
PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel
Yong Zhang et al.
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE (2010)
Parkinson's Psychosis
Laura B. Zahodne et al.
CURRENT TREATMENT OPTIONS IN NEUROLOGY (2010)
Increased 5-HT2A Receptors in the Temporal Cortex of Parkinsonian Patients with Visual Hallucinations
Philippe Huot et al.
MOVEMENT DISORDERS (2010)
Dopamine Agonists and their risk to induce psychotic episodes in Parkinson's disease: a case-control study
Daniel Ecker et al.
BMC NEUROLOGY (2009)
Hallucinations in Parkinson disease
Nico J. Diederich et al.
NATURE REVIEWS NEUROLOGY (2009)
The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years
Mariese A. Hely et al.
MOVEMENT DISORDERS (2008)
Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in Parkinsonian rats
Manolo Carta et al.
BRAIN (2007)
In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\increased motor disability
Mahmoud M. Iravani et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years
MA Hely et al.
MOVEMENT DISORDERS (2005)
Presynaptic mechanisms of motor fluctuations in Parkinson's disease:: a probabilistic model
R de la Fuente-Fernández et al.
BRAIN (2004)
Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease
MP Hill et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Pharmacokinetics of three formulations of ondansetron hydrochloride in healthy volunteers: 24-mg oral tablet, rectal suppository, and i.v. infusion
CM VanDenBerg et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2000)
分享论文
